Expert opinions on sustainable weight loss: Insights from leading authorities

To explore the topic of sustainable weight loss, Health Tech World gathered three experts for an insightful webinar. Dr. Martin Carlsson, co-founder of Yazen, emphasized the importance of a multidisciplinary approach to weight management. According to Dr. Carlsson, a combination of medication, lifestyle changes, and continuous support from a multidisciplinary team of healthcare professionals—including doctors, YazenCoaches, dietitians, psychologists, and personal trainers—is crucial for achieving long-term success in weight loss.

Simon Pickup, Head of Health at Sweatcoin, highlighted the role of physical activity in weight management. He pointed out that digital health apps and wearables are making it easier for individuals to track their physical activity, set goals, and stay motivated. These tools provide real-time feedback and personalised recommendations, helping users to make informed decisions about their health and fitness routines.

Dr. Neel Gupta, UK Medical Lead at Oviva, focused on the importance of nutrition and behavioral changes. He stressed that sustainable weight loss requires a holistic approach that addresses both the physiological and psychological aspects of obesity. Personalised meal plans, regular counseling sessions, and continuous monitoring are essential components of a successful weight loss program.

The experts agreed that while novel antiobesity-medications such as semaglutide and tirzepatide are powerful tools, they should be used in conjunction with other strategies to ensure sustainable, long-lasting results. A patient-centric approach that considers individual needs and preferences is key to achieving and maintaining weight loss goals.

Listen to our CMO, Dr. Martin Carlsson, discuss the latest on obesity treatment

Dr. Martin Carlsson, a leading authority on obesity treatment and co-founder of Yazen, shared his insights on the latest advancements in obesity treatment during the recent Health Tech World webinar. Dr. Carlsson discussed the transformative impact of medications like Ozempic, Wegovy, Mounjaro and other novel anti-obesity medications and the importance of integrating these treatments with lifestyle changes and professional support.

Dr. Carlsson emphasized that the key to successful obesity treatment lies in a comprehensive, patient-centric approach. He highlighted the role of digital health tools and innovations in improving patient engagement and outcomes. According to Dr. Carlsson, combining medication, personalised care, and continuous support from a multidisciplinary team is essential for achieving sustainable weight loss.

For those who missed the webinar, a recording is available on YouTube, providing an opportunity to learn from leading experts in the field of weight management. Dr. Carlsson's discussion offers valuable insights into the latest trends and best practices in obesity treatment, making it a must-watch for patients and healthcare professionals alike.

The future of weight management tools: Embracing innovation for better health outcomes

Technological advancements and innovative approaches to healthcare are shaping the future of weight management. Digital health tools, such as apps and wearables, are pivotal in this evolution. These tools provide valuable insights into a person's health behaviors and offer personalised guidance that can help users make healthier choices.

Wearable devices, such as fitness trackers and smartwatches, monitor physical activity, heart rate, sleep patterns, and other health metrics. They enable users to set and track goals, receive real-time feedback, and stay motivated on their weight loss journey. These devices also facilitate the collection of data that can be used by healthcare professionals to tailor interventions and provide more effective support.

Digital health apps are also transforming the weight management landscape. Apps like MyFitnessPal, Noom, and others offer features such as calorie tracking, meal planning, and virtual coaching. These apps use artificial intelligence and machine learning to provide personalized recommendations and adapt to the user's progress over time. Integrating these tools with telehealth services allows for continuous monitoring and support, making it easier for patients to adhere to their weight loss plans.

Emerging technologies, such as virtual reality (VR) and augmented reality (AR), hold promise for further enhancing weight management strategies. VR and AR can create immersive experiences that educate and motivate users, helping them to develop healthier habits and overcome challenges. For example, VR can simulate real-life scenarios to practice mindful eating or guide users through virtual fitness sessions.

Semaglutide and tirzepatide Weight loss benefits: A game changer in medical weight management

Ozempic and Wegovy, brand names for semaglutide and Mounjaro, brand name for tirzepatide, have emerged as revolutionary medications in the field of weight management. Originally used for type 2 diabetes, these medications now have garnered significant attention for it´s efficacy  in promoting weight loss. Patients on a weight loss journey often face multiple challenges, and Ozempic, Wegovy, Mounjaro and other GLP-1 medications provide a substantial boost by addressing one of the most critical aspects: appetite control.

Ozempic and Wegovy works by mimicking the effects of the hormone GLP-1 (glucagon-like peptide-1), which regulates appetite and food intake. By binding to GLP-1 receptors, the medication not only helps in managing blood sugar levels but also reduces hunger pangs, leading to significant weight loss. Clinical trials have shown that patients using Ozempic can lose an average of 12-16% of their body weight after one year, making it one of the most effective weight loss medications currently available.

The benefits of Ozempic and Wegovy c extend beyond weight loss. Patients report improved blood sugar control, reduced risk of cardiovascular diseases, and an overall enhancement in quality of life. 

Mounjaro and Zepbound (tirzepatide) is a newer drug that acts on both the GLP-1 and GIP hormones. It is a so-called dual GIP and GLP-1 receptor agonist. This novel medicine has also been shown in studies to have a very good weight-reducing and blood-sugar-lowering effect. In one study, the overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide. 

As a part of a comprehensive weight loss program that includes lifestyle changes and professional support, these medications have the potential to transform the landscape of obesity treatment.

‍

Listen to the webinar on Health Tech World's website: 

https://www.htworld.co.uk/exclusive/watch-weight-management-innovations-for-long-lasting-change/

‍

‍